活动性丙型肝炎病毒感染的 deceased 供肾中肾小球肾炎患病率低
研究纳入147例HCV-RNA阳性供肾与431例HCV阴性供肾的多中心组织学数据库,比较肾小球肾炎和慢性病变病理的患病率。专家病理复核显示两组肾小球疾病和孤立免疫复合物沉积均罕见,主要结局非劣效,HCV阳性供肾受者12个月eGFR与阴性组无显著差异。
要点
- HCV-RNA阳性供肾中肾小球疾病罕见,慢性病变病理不高于HCV阴性供肾。
- 主要结局肾小球硬化、间质纤维化伴肾小管萎缩和/或血管病变在15%界值下非劣效。
- HCV-RNA阳性供肾受者12个月eGFR较阴性组高1.65 ml/min/1.73 m2,无显著差异。
核心结论
- HCV-RNA阳性供肾中肾小球疾病罕见,慢性病变病理不高于HCV阴性供肾,可能让临床医生放心考虑这些器官。
研究设计与样本
- 多中心组织学数据库,比较147例HCV-RNA阳性供肾与431例HCV阴性供肾的肾小球肾炎和慢性病变病理患病率。
主要发现
- HCV-RNA阳性与HCV阴性供肾平均年龄分别为40.3岁与40.7岁。
- 肾小球硬化<5%者HCV-RNA阳性供肾61.2% vs HCV阴性供肾49%。
- 间质纤维化伴肾小管萎缩<5%者HCV-RNA阳性供肾68% vs HCV阴性供肾58%。
- 无血管病变者HCV-RNA阳性供肾46% vs HCV阴性供肾25%。
- 12个月eGFR在HCV-RNA阳性供肾受者较HCV阴性对照高1.65 ml/min/1.73 m2,组间无显著差异。
关键数值与推荐
- 主要结局肾小球硬化、间质纤维化伴肾小管萎缩和/或血管病变在15%界值下非劣效。
临床怎么用
- 作者认为HCV-RNA阳性供肾中肾小球疾病罕见且慢性病变病理不更常见,可能让临床医生放心考虑这些器官用于患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hepatitis C virus (HCV) infection is a leading cause of immune-complex mediated glomerulonephritis, specifically cryoglobulinemic and membranoproliferative glomerulonephritis, and has also been associated with non-glomerular kidney diseases. However, the prevalence of kidney disease among individuals with chronic HCV infection is unknown. Concerns about the quality of kidneys from deceased donors with HCV infection may lead centers to avoid transplanting these organs. METHODS: We assembled a multicenter histological database of deceased donor biopsies to compare the prevalence of glomerulonephritis and chronic disease pathology among 147 transplanted kidneys from HCV-RNA+ donors matched to 431 HCV-negative donors. RESULTS: The mean age was 40.3 versus 40.7 years for HCV-RNA+ versus HCV-negative donors, respectively. Expert pathology reviews showed that glomerular disease and isolated immune complex deposition were rare in both groups. The primary outcome of glomerulosclerosis, interstitial fibrosis with tubular atrophy, and/or vascular disease was non-inferior (15% margin) for HCV-RNA+ versus HCV-negative donor kidneys. Specifically, 61.2% versus 49% had under 5% glomerulosclerosis, 68% versus 58% had under 5% interstitial fibrosis with tubular atrophy, and 46% versus 25% had no vascular disease, for HCV-RNA+ versus HCV-negative donor kidneys, respectively. The recipients of kidney transplants from HCV-RNA+ donors and HCV-negative comparators both demonstrated good graft function and 12-month eGFR was not significantly different between groups (1.65 ml/min/1.73 m2 higher eGFR for HCV-RNA+ allograft recipients.) CONCLUSIONS: Our findings indicate that for HCV-RNA+ donor kidneys, glomerular disease was rare and chronic disease pathology was not more common than among HCV-negative kidneys, which may reassure clinicians to consider these organs for their patients.
引用
- Reese PP, Mohan S, Schaubel DE, et al. Low prevalence of glomerulonephritis in transplanted kidneys from deceased donors with active hepatitis C virus infection. Kidney Int. 2025. PMID: 40850617. doi:10.1016/j.kint.2025.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。